BEST UNLIMITED TURBO SHORT CERTIFICATE - BRISTOL-MYERS SQUIBB | Real-time Euronext Paris 06:03:45 2024-05-15 EDT | ||
| 2.775 EUR | -1.07% |
|
| Current month | -1.41% | ||
| 1 month | +35.84% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Latest news about BRISTOL-MYERS SQUIBB COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 24-05-15 | 2.775 | -1.07% |
| 24-05-14 | 2.805 | +2.94% |
| 24-05-13 | 2.725 | -2.85% |
| 24-05-10 | 2.805 | -5.40% |
| 24-05-09 | 2.965 | -1.00% |
Real-time Euronext Paris
Last update May 15, 2024 at 06:03 am
More quotesStatic data
| Product type | Certificat Turbo |
|---|---|
| Buy / Sell | PUT |
| Underlying | BRISTOL-MYERS SQUIBB COMPANY |
| Issuer | 
Société Générale
|
| U663S | |
| ISIN | DE000SU675M9 |
| Date issued | 2024-01-22 |
| Strike | 59.58 $ |
| Maturity | Unlimited |
| Parity | 5 : 1 |
| Emission price | 1.88 € |
| Emission volume | N/A |
| Settlement | règlement en espèces |
| Currency | EUR |
Technical Indicators
| Highest since issue | 3.065 € |
|---|---|
| Lowest since issue | 1.01 € |
| Spread | 0.03 € |
| Spread % | 1.08% |
Company Profile
Bristol-Myers Squibb Company est spécialisé dans le développement, la fabrication et la commercialisation de produits pharmaceutiques. Les produits sont destinés au traitement des cancers, des maladies cardio-vasculaires, de l'hépatite, des maladies immunitaires et des désordres psychiatriques.
The United States account for 70.1% of net sales.
Sector
-
Ratings for Bristol-Myers Squibb Company
Trading Rating
Investor Rating
ESG Refinitiv
B
Consensus: Bristol-Myers Squibb Company
Sell
Buy
Mean consensus
HOLD
Number of Analysts
25
Last Close Price
44.71
USD
Average target price
53.19
USD
Spread / Average Target
+18.98%
- Stock Market
- Certificates
- U663S Certificat